Werewolf Therapeutics (HOWL) Enterprise Value (2021 - 2026)

Werewolf Therapeutics (HOWL) has reported Enterprise Value for 6 consecutive years, with -$4.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value rose 84.02% year-over-year to -$4.5 million in Q2 2026; TTM through Jun 2026 was -$4.5 million, a 84.02% increase from a year earlier, with the FY2025 full-year figure at -$26.4 million, up 40.8% from the prior year.
• Enterprise Value was -$4.5 million for Q2 2026 at Werewolf Therapeutics, up from -$6.2 million in the prior quarter.
• Over five years, Enterprise Value peaked at $141.3 million in Q1 2024 and troughed at -$64.9 million in Q4 2022.
• A 5-year average of -$16.2 million and a median of -$28.4 million in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value sank 2144.83% in 2023 and jumped 351.9% in 2024, its largest moves.
• Over 5 years, Enterprise Value stood at -$64.9 million in 2022, then soared by 125.6% to $16.6 million in 2023, then plunged by 368.82% to -$44.7 million in 2024, then jumped by 40.8% to -$26.4 million in 2025, then surged by 82.96% to -$4.5 million in 2026.
• The last three Enterprise Value figures came in at -$4.5 million (Q2 2026), -$6.2 million (Q1 2026), and -$26.4 million (Q4 2025), per Business Quant data.